Market closedNon-fractional
Tyra Biosciences/TYRA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Tyra Biosciences
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
Ticker
TYRA
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Carlsbad, United States
Employees
49
Website
tyra.bio
Tyra Biosciences Metrics
BasicAdvanced
$1.1B
Market cap
-
P/E ratio
-$1.67
EPS
1.08
Beta
-
Dividend rate
Price and volume
Market cap
$1.1B
Beta
1.08
Financial strength
Current ratio
44.835
Quick ratio
44.053
Long term debt to equity
1.569
Total debt to equity
1.664
Management effectiveness
Return on assets (TTM)
-16.66%
Return on equity (TTM)
-23.63%
Valuation
Price to book
2.71
Price to tangible book (TTM)
2.71
Price to free cash flow (TTM)
-14.546
Growth
Earnings per share change (TTM)
34.25%
3-year earnings per share growth (CAGR)
-38.28%
What the Analysts think about Tyra Biosciences
Analyst Ratings
Majority rating from 6 analysts.
Tyra Biosciences Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$18M
-20.61%
Profit margin
0.00%
NaN%
Tyra Biosciences Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.31
-$0.49
-$0.53
-$0.35
-
Expected
-$0.34
-$0.35
-$0.48
-$0.46
-$0.41
Surprise
-9.80%
38.94%
10.26%
-23.11%
-
Tyra Biosciences News
AllArticlesVideos
Tyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia (HCH)
PRNewsWire·3 weeks ago
Tyra Biosciences to Present at Upcoming Investor Conferences
PRNewsWire·2 months ago
Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights
PRNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Tyra Biosciences stock?
Tyra Biosciences (TYRA) has a market cap of $1.1B as of July 27, 2024.
What is the P/E ratio for Tyra Biosciences stock?
The price to earnings (P/E) ratio for Tyra Biosciences (TYRA) stock is 0 as of July 27, 2024.
Does Tyra Biosciences stock pay dividends?
No, Tyra Biosciences (TYRA) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Tyra Biosciences dividend payment date?
Tyra Biosciences (TYRA) stock does not pay dividends to its shareholders.
What is the beta indicator for Tyra Biosciences?
Tyra Biosciences (TYRA) has a beta rating of 1.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Tyra Biosciences stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.